Headquartered in Dublin, Ireland, ATXA Therapeutics Limited is a spin-out company from University College Dublin whose primary focus is to advance clinical trials and to secure marketing authorization of novel therapies for the treatment of Pulmonary Arterial Hypertension (PAH), serving a previously unmet medical need by offering improved treatment options to the prescribing physician and new hope for the PAH patient.


Founded by Professor Therese Kinsella MRIA, ATXA was incorporated in May 2015 and is the culmination of over 20 years of extensive research and in excess of €15m prior grant funding, along with a proven track record in elucidating the biology and signalling of the human prostanoid receptors in the cardiovascular, oncology and other disease settings.  


In the past, the company has received funding support from several technology and commercialization development grants from Enterprise Ireland and Science Foundation Ireland.  Through its initial drug-development phase, ATXA has developed a series of novel, highly selective small molecule drugs and validated their potential use through preclinical efficacy evaluation in several target disease indications including in thrombosis/cardiovascular, oncology, anti-inflammatory and, most particularly, in PAH disease indications. 


Most recently, during 2018, ATXA was successful in winning €2.5 million grant aid through the European Union’s highly competitive and prestigious Horizon 2020 SME Instrument funding scheme that supports the leading disruptive innovations across EU member states.  The activities associated with ATXA’s EU-funded SME Instrument program, dubbed PAH-HOPE, got underway on 1st October 2018 and will fast-track ATXA’s lead drug NTP42 into clinical development.


The ATXA team has expertise in cardiovascular and cancer biology with technical know-how in platelet biology, cellular and molecular biology, protein biology, pathological and histopathological and immunohistochemical techniques, digital pathology and biostatistics. In addition, ATXA’s team has extensive experience in drug discovery and early development; lead generation; lead optimization; candidate selection; medicinal chemistry; preclinical pharmacokinetics; intellectual property management and commercialization.

ATXA’s drug leads are protected by an extensive and growing patent estate granted through the EPO (Europe) and the USPTO (USA), with several others filed including in other territories.  Moreover, in 2018, ATXA secured Orphan Designation from the EMA (Europe) and the FDA (USA) for its lead drug NTP42 for its primary target indication PAH.

ATXA Therapeutics Ltd will advance the late-stage development of their novel therapies that display substantial improvements over the existing standard-of-care, addressing critical unmet medical needs for efficacious new therapies to treat PAH.

ATXA Therapeutics Ltd. is a company on a mission... to offer new hope to the PAH patient.